Nab-paclitaxel plus bevacizumab for patients with metastatic extrapulmonary neuroendocrine carcinoma: a phase 2 single-arm study
This study was partially supported by Qilu Pharmaceutical Co., Ltd. This work is supported by the Beijing Municipal Science & Technology Commission (No. Z231100007223002).
Authors
- Jing Hao (ORCID: https://orcid.org/0000-0002-8512-1826)
- Shilin Gan
- Lin Shen (ORCID: https://orcid.org/0000-0002-8798-4756)
- Shengmian Li (ORCID: https://orcid.org/0000-0002-3613-7856)
- Chen Chen (ORCID: https://orcid.org/0009-0009-6907-2487)
- Jie Li (ORCID: https://orcid.org/0000-0003-0973-8645)
- Ming‐De Lu (ORCID: https://orcid.org/0000-0002-9771-8144)
- Ru Jia (ORCID: https://orcid.org/0000-0003-4446-1039)
- Panpan Zhang (ORCID: https://orcid.org/0000-0002-8187-6455)
Institutions
- Hebei Medical University (CN)
- Peking University (CN)
- Chinese PLA General Hospital (CN)
- Peking University Cancer Hospital (CN)
- Beijing Biocytogen (China) (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Ministry of Education (ET)
- Beijing Fengtai Hospital (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103598
- Citations
- 2
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 2.71